AI assistant
Stoke Therapeutics, Inc. — Director's Dealing 2024
Jun 7, 2024
32172_dirs_2024-06-07_1518a944-45a4-45f7-bf48-a033572f35dd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2024-03-27
Reporting Person: Allan Jonathan (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-27 | Employee Stock Option (Right to Buy) | $14.17 | A | 36000 | Acquired | 2034-03-26 | Common Stock (36000) | Direct |
| 2024-03-27 | Restricted Stock Units | $ | A | 24000 | Acquired | 2028-03-15 | Common Stock (24000) | Direct |
Footnotes
F1: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.